Skip to content

Study · Randomized controlled trial · n = 500 · 2021

16 results

Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling.

Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss RJ

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA26 Jan 2021Cited by 39 (Europe PMC)

PMID33496831 (opens in a new tab)PMCIDPMC7929959 (opens in a new tab)DOI10.1007/s00198-020-05806-1 (opens in a new tab)PepBankPUB-33496831
Read at sourcePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study16

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide produced significantly greater changes in cortical volumetric BMD than teriparatide.

    In plain wordsIn women with osteoporosis, abaloparatide produced significantly greater changes in cortical volumetric BMD than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCortical volumetric BMD change
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide produced significantly greater changes in cortical surface BMD than teriparatide.

    In plain wordsIn women with osteoporosis, abaloparatide produced significantly greater changes in cortical surface BMD than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCortical surface BMD change
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide and teriparatide showed similar increases in trabecular volumetric BMD at 18 months.

    In plain wordsIn women with osteoporosis, abaloparatide and teriparatide showed similar increases in trabecular volumetric BMD at 18 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changetrabecular volumetric BMD between treatments
    Study

    n = 500

    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide and teriparatide showed similar increases in cortical thickness at 18 months.

    In plain wordsIn women with osteoporosis, abaloparatide and teriparatide showed similar increases in cortical thickness at 18 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changecortical thickness between treatments
    Study

    n = 500

    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, abaloparatide increased trabecular volumetric BMD by 9% from baseline.

    In plain wordsIn women with osteoporosis, abaloparatide increased trabecular bone density by 9% from baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTrabecular volumetric BMD
    Study

    n = 250

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · 18 monthsAs given in this study (human).

    Measurements

    Trabecular vBMD change
    9%
    18 months

    Source sentences

    Summary
    Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide increased cortical thickness by 1.5% from baseline.

    In plain wordsIn women with osteoporosis, abaloparatide increased cortical thickness by 1.5% from baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCortical thickness
    Study

    n = 250

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · 18 monthsAs given in this study (human).

    Measurements

    Cortical thickness change
    1.5%
    18 months

    Source sentences

    Summary
    Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide significantly increased cortical volumetric BMD by 1.3% from baseline.

    In plain wordsIn women with osteoporosis, abaloparatide increased cortical bone density by 1.3% from baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCortical volumetric BMD
    Study

    n = 250

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · 18 monthsAs given in this study (human).

    Measurements

    Cortical vBMD change
    1.3%
    18 months

    Source sentences

    Summary
    In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  8. 08HumanObservational studyEfficacy outcome

    In women with osteoporosis, teriparatide produced significantly smaller changes in cortical volumetric BMD than abaloparatide.

    In plain wordsIn women with osteoporosis, teriparatide produced significantly smaller changes in cortical volumetric BMD than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCortical volumetric BMD change
    Study

    n = 500

    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  9. 09HumanObservational studyEfficacy outcome

    In women with osteoporosis, teriparatide produced significantly smaller changes in cortical surface BMD than abaloparatide.

    In plain wordsIn women with osteoporosis, teriparatide produced significantly smaller changes in cortical surface BMD than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCortical surface BMD change
    Study

    n = 500

    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  10. 10HumanObservational studyEfficacy outcome

    In women with osteoporosis, teriparatide and abaloparatide showed similar increases in trabecular volumetric BMD at 18 months.

    In plain wordsIn women with osteoporosis, teriparatide and abaloparatide showed similar increases in trabecular volumetric BMD at 18 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changetrabecular volumetric BMD between treatments
    Study

    n = 500

    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  11. 11HumanObservational studyEfficacy outcome

    In women with osteoporosis, teriparatide and abaloparatide showed similar increases in cortical thickness at 18 months.

    In plain wordsIn women with osteoporosis, teriparatide and abaloparatide showed similar increases in cortical thickness at 18 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changecortical thickness between treatments
    Study

    n = 500

    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  12. 12HumanObservational studyEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide increased trabecular volumetric BMD by 9% from baseline.

    In plain wordsIn women with osteoporosis, teriparatide increased trabecular bone density by 9% from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular volumetric BMD
    Study

    n = 250

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg · 18 monthsAs given in this study (human).

    Measurements

    Trabecular vBMD change
    9%
    18 months

    Source sentences

    Summary
    Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  13. 13HumanObservational studyEfficacy outcome

    In women with osteoporosis, teriparatide increased cortical thickness by 1.5% from baseline.

    In plain wordsIn women with osteoporosis, teriparatide increased cortical thickness by 1.5% from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCortical thickness
    Study

    n = 250

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg · 18 monthsAs given in this study (human).

    Measurements

    Cortical thickness change
    1.5%
    18 months

    Source sentences

    Summary
    Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.
  14. 14HumanObservational studyEfficacy outcome

    In women with osteoporosis, teriparatide did not significantly increase cortical volumetric BMD from baseline.

    In plain wordsIn women with osteoporosis, teriparatide did not significantly increase cortical bone density from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCortical volumetric BMD
    Study

    n = 250

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 15HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyMechanism

    In teriparatide-treated women, cortical volumetric BMD changes were inversely associated with serum CTX changes.

    In plain wordsIn women receiving teriparatide, cortical bone density changes were inversely linked to serum CTX changes.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCortical vBMD association with CTX
    Study

    n = 250

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In the TPTD group, changes in cortical vBMD were inversely correlated with changes in serum CTX (carboxy-terminal telopeptide of type I collagen) and PINP (procollagen type I N-terminal propeptide), suggesting that higher bone turnover may have attenuated cortical gains.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 16HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyMechanism

    In teriparatide-treated women, cortical volumetric BMD changes were inversely associated with serum PINP changes.

    In plain wordsIn women receiving teriparatide, cortical bone density changes were inversely linked to serum PINP changes.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCortical vBMD association with PINP
    Study

    n = 250

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In the TPTD group, changes in cortical vBMD were inversely correlated with changes in serum CTX (carboxy-terminal telopeptide of type I collagen) and PINP (procollagen type I N-terminal propeptide), suggesting that higher bone turnover may have attenuated cortical gains.
    1 context sentence
    Summary · context
    Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.